A Meta-Analysis of Cytokines in Alzheimer's Disease

[1]  P. Libby.  Inflammation in Atherosclerosis , 2012, Arteriosclerosis, thrombosis, and vascular biology.

[2]  H. Hanyu,et al.  Efficacy of PPAR-γ agonist pioglitazone in mild Alzheimer disease , 2011, Neurobiology of Aging.

[3]  Brad J Kolls,et al.  A PHASE 2 MULTIPLE ASCENDING DOSE TRIAL OF BAPINEUZUMAB IN MILD TO MODERATE ALZHEIMER DISEASE , 2010, Neurology.

[4]  Sudha Seshadri,et al.  Genome-wide analysis of genetic loci associated with Alzheimer disease. , 2010, JAMA.

[5]  O. Forlenza,et al.  Increased Serum IL-1β Level in Alzheimer’s Disease and Mild Cognitive Impairment , 2009, Dementia and Geriatric Cognitive Disorders.

[6]  M. Schwartz,et al.  Attenuation of AD‐like neuropathology by harnessing peripheral immune cells: local elevation of IL‐10 and MMP‐9 , 2009, Journal of neurochemistry.

[7]  M. Leon,et al.  TNF-α and antibodies to periodontal bacteria discriminate between Alzheimer's disease patients and normal subjects , 2009, Journal of Neuroimmunology.

[8]  A. Kiss,et al.  Indoleamine 2,3-dioxygenase activation and depressive symptoms in patients with coronary artery disease , 2009, Psychoneuroendocrinology.

[9]  N. Relkin,et al.  18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease , 2009, Neurobiology of Aging.

[10]  B. Okopień,et al.  The effects of 1 month antihypertensive treatment with perindopril, bisoprolol or both on the ex vivo ability of monocytes to secrete inflammatory cytokines. , 2009, International journal of clinical pharmacology and therapeutics.

[11]  Xiang Cheng,et al.  Relationship between plasma inflammatory markers and plaque fibrous cap thickness determined by intravascular optical coherence tomography , 2009, Heart.

[12]  C. Hong,et al.  Peripheral Cytokines and Chemokines in Alzheimer’s Disease , 2009, Dementia and Geriatric Cognitive Disorders.

[13]  J. Ioannidis,et al.  The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. , 2009, Journal of clinical epidemiology.

[14]  L. Kiemeney,et al.  Corrigendum: Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer , 2009, Nature Genetics.

[15]  V. Perry,et al.  Systemic inflammation and disease progression in Alzheimer disease , 2009, Neurology.

[16]  Nick C Fox,et al.  Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease, and shows evidence for additional susceptibility genes , 2009, Nature Genetics.

[17]  P. Bosco,et al.  Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease , 2009, Nature Genetics.

[18]  C. Polanczyk,et al.  Interleukin-18: an independent predictor of cardiovascular events in patients with acute coronary syndrome after 6 months of follow-up , 2009, Coronary Artery Disease.

[19]  C. Caltagirone,et al.  Disease outcome, alexithymia and depression are differently associated with serum IL-18 levels in acute stroke. , 2009, Current neurovascular research.

[20]  Gilles J. Guillemin,et al.  The Excitotoxin Quinolinic Acid Induces Tau Phosphorylation in Human Neurons , 2009, PloS one.

[21]  W. M. van der Flier,et al.  CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. , 2009, JAMA.

[22]  S. Normand,et al.  Syncope and its consequences in patients with dementia receiving cholinesterase inhibitors: a population-based cohort study. , 2009, Archives of internal medicine.

[23]  W. Banks,et al.  Lipopolysaccharide alters the blood–brain barrier transport of amyloid β protein: A mechanism for inflammation in the progression of Alzheimer’s disease , 2009, Brain, Behavior, and Immunity.

[24]  J. Pons,et al.  Suppression of Amyloid Deposition Leads to Long-Term Reductions in Alzheimer's Pathologies in Tg2576 Mice , 2009, The Journal of Neuroscience.

[25]  R. Gibson,et al.  Transport of interleukin‐1 across cerebromicrovascular endothelial cells , 2009, British journal of pharmacology.

[26]  Colin L Masters,et al.  Aβ aggregation and possible implications in Alzheimer's disease pathogenesis , 2009, Journal of cellular and molecular medicine.

[27]  V. Pavlov,et al.  Brain acetylcholinesterase activity controls systemic cytokine levels through the cholinergic anti-inflammatory pathway , 2009, Brain, Behavior, and Immunity.

[28]  T. Montine,et al.  Modulation of microglial innate immunity in Alzheimer's disease by activation of peroxisome proliferator-activated receptor gamma. , 2009, Current medicinal chemistry.

[29]  Zhong-lin Liu,et al.  Expression and genetic analysis of tumor necrosis factor-α (TNF-α) G-308A polymorphism in sporadic Alzheimer's disease in a Southern China population , 2009, Brain Research.

[30]  Min-Jeong Shin,et al.  Bioplex analysis of plasma cytokines in Alzheimer's disease and mild cognitive impairment. , 2008, Immunology letters.

[31]  J. Higgins,et al.  Meta-Regression in Stata , 2008 .

[32]  A. Luster,et al.  Mechanisms of microglia accumulation in Alzheimer's disease: therapeutic implications. , 2008, Trends in pharmacological sciences.

[33]  Robert C. Green,et al.  Effects of cardiovascular medications on rate of functional decline in Alzheimer disease. , 2008, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[34]  A. Passaro,et al.  Markers of endothelial dysfunction in older subjects with late onset Alzheimer's disease or vascular dementia , 2008, Journal of the Neurological Sciences.

[35]  T. Connor,et al.  Induction of indolamine 2,3-dioxygenase and kynurenine 3-monooxygenase in rat brain following a systemic inflammatory challenge: A role for IFN-γ? , 2008, Neuroscience Letters.

[36]  Ute Resch-Genger,et al.  An international comparability study to determine the sources of uncertainty associated with a non-competitive sandwich fluorescent ELISA , 2008, Clinical chemistry and laboratory medicine.

[37]  Lidia Glodzik-Sobanska,et al.  Inflammation and Alzheimer's disease: Possible role of periodontal diseases , 2008, Alzheimer's & Dementia.

[38]  J. Growdon,et al.  Plasma amyloid beta-protein and C-reactive protein in relation to the rate of progression of Alzheimer disease. , 2008, Archives of neurology.

[39]  Chulhee Choi,et al.  Multiplex Analysis of Cytokines in the Serum and Cerebrospinal Fluid of Patients With Alzheimer's Disease by Color-Coded Bead Technology , 2008, Journal of clinical neurology.

[40]  Jun Tan,et al.  Blocking TGF-β–Smad2/3 innate immune signaling mitigates Alzheimer-like pathology , 2008, Nature Medicine.

[41]  P. Gil,et al.  Differences of peripheral inflammatory markers between mild cognitive impairment and Alzheimer's disease. , 2008, Immunology letters.

[42]  C. Caltagirone,et al.  Interleukin-18 produced by peripheral blood cells is increased in Alzheimer’s disease and correlates with cognitive impairment , 2008, Brain, Behavior, and Immunity.

[43]  Jing Zhang,et al.  CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases. , 2008, American journal of clinical pathology.

[44]  A. Özge,et al.  The Diagnostic Role of Serum Inflammatory and Soluble Proteins on Dementia Subtypes: Correlation with Cognitive and Functional Decline , 2008, Behavioural neurology.

[45]  Douglas G. Altman,et al.  Metan: Fixed- and Random-Effects Meta-Analysis , 2008 .

[46]  M. Barcikowska,et al.  Plasma beta amyloid and cytokine profile in women with Alzheimer's disease. , 2008, Neuro endocrinology letters.

[47]  J. Encke,et al.  Pharmacologic cholinesterase inhibition improves survival in experimental sepsis* , 2008, Critical care medicine.

[48]  Stavros J. Baloyannis,et al.  Systemic immune aberrations in Alzheimer's disease patients , 2008, Journal of Neuroimmunology.

[49]  V. Costa,et al.  Cytokines in Alzheimer's Disease and Vascular Dementia , 2008, The International journal of neuroscience.

[50]  O. Combarros,et al.  Serum levels and genetic variation of TGF‐β1 are not associated with Alzheimer’s disease , 2007, Acta neurologica Scandinavica.

[51]  F. Stivala,et al.  Altered plasma cytokine levels in Alzheimer's disease: correlation with the disease progression. , 2007, Immunology letters.

[52]  R. Green,et al.  Vascular factors predict rate of progression in Alzheimer disease , 2007, Neurology.

[53]  Cheng-Hsien Lu,et al.  Level and value of interleukin-18 after acute ischemic stroke. , 2007, Circulation journal : official journal of the Japanese Circulation Society.

[54]  R. Guerreiro,et al.  Peripheral Inflammatory Cytokines as Biomarkers in Alzheimer’s Disease and Mild Cognitive Impairment , 2007, Neurodegenerative Diseases.

[55]  S. Volpato,et al.  Plasma cytokines profile in older subjects with late onset Alzheimer's disease or vascular dementia. , 2007, Journal of psychiatric research.

[56]  D. Fuchs,et al.  Cognitive deterioration in Alzheimer's disease is accompanied by increase of plasma neopterin. , 2007, Journal of psychiatric research.

[57]  J. Ramchandani,et al.  Potential biomarkers for dementia in Trinidad and Tobago , 2007, Neuroscience Letters.

[58]  E. B. Larson,et al.  Statin Therapy Is Associated with Reduced Neuropathologic Changes Statin Therapy Is Associated with Reduced Neuropathologic Changes of Alzheimer Disease , 2022 .

[59]  A. Rudensky,et al.  Foxp3 in control of the regulatory T cell lineage , 2007, Nature Immunology.

[60]  C. Geula,et al.  Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease , 2007, Nature Medicine.

[61]  R. Cacabelos,et al.  Serum TNF-alpha levels are increased and correlate negatively with free IGF-I in Alzheimer disease , 2007, Neurobiology of Aging.

[62]  S. Volpato,et al.  High interleukin‐6 plasma levels are associated with functional impairment in older patients with Vascular dementia , 2007, International journal of geriatric psychiatry.

[63]  Claudius Mueller,et al.  Increased production of inflammatory cytokines in mild cognitive impairment , 2007, Experimental Gerontology.

[64]  G. Davı̀,et al.  Determinants of platelet activation in Alzheimer's disease , 2007, Neurobiology of Aging.

[65]  Colm Cunningham,et al.  Systemic infections and inflammation affect chronic neurodegeneration , 2007, Nature Reviews Immunology.

[66]  P. Aisen,et al.  A Phase II study targeting amyloid-β with 3APS in mild-to-moderate Alzheimer disease , 2006, Neurology.

[67]  Elisabeth Kapaki,et al.  Interleukin-12 is reduced in cerebrospinal fluid of patients with Alzheimer's disease and frontotemporal dementia , 2006, Journal of the Neurological Sciences.

[68]  A. Gamian,et al.  Analysis of Serum of Patients With Alzheimer’s Disease for the Level of Advanced Glycation End Products , 2006, American journal of Alzheimer's disease and other dementias.

[69]  Tony Wyss-Coray,et al.  Inflammation in Alzheimer disease: driving force, bystander or beneficial response? , 2006, Nature Medicine.

[70]  D. Sparks,et al.  Change in circulating C-reactive protein is not associated with atorvastatin treatment in Alzheimer's disease , 2006, Neurological research.

[71]  M. Malaguarnera,et al.  Interleukin‐18 and transforming growth factor‐beta 1 plasma levels in Alzheimer’s disease and vascular dementia , 2006, Neuropathology : official journal of the Japanese Society of Neuropathology.

[72]  K. Kuroda,et al.  Serum BDNF, TNF-alpha and IL-1beta levels in dementia patients: comparison between Alzheimer's disease and vascular dementia. , 2006, European archives of psychiatry and clinical neuroscience.

[73]  A. Rombos,et al.  IL-15 Is Elevated in Cerebrospinal Fluid of Patients With Alzheimer’s Disease and Frontotemporal Dementia , 2006, Journal of geriatric psychiatry and neurology.

[74]  S. Mayer,et al.  Hematoma growth is a determinant of mortality and poor outcome after intracerebral hemorrhage , 2006, Neurology.

[75]  N. Bresolin,et al.  Intrathecal chemokine synthesis in mild cognitive impairment and Alzheimer disease. , 2006, Archives of neurology.

[76]  B. Bergamasco,et al.  Increased intrathecal TGF-β1, but not IL-12, IFN-γ and IL-10 levels in Alzheimer’s disease patients , 2006, Neurological Sciences.

[77]  Bogdan Tanasa,et al.  Regulation of Th2 differentiation and Il4 locus accessibility. , 2006, Annual review of immunology.

[78]  R. J. Hocking,et al.  TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. , 2006, Immunity.

[79]  D. Fuchs,et al.  Monitoring tryptophan metabolism in chronic immune activation. , 2006, Clinica chimica acta; international journal of clinical chemistry.

[80]  H. Hinterhuber,et al.  Measurement of Thirteen Biological Markers in CSF of Patients with Alzheimer’s Disease and Other Dementias , 2005, Dementia and Geriatric Cognitive Disorders.

[81]  Hendrik van den Bussche,et al.  Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials , 2005, BMJ : British Medical Journal.

[82]  B. Brew,et al.  Indoleamine 2,3 dioxygenase and quinolinic acid Immunoreactivity in Alzheimer's disease hippocampus , 2005, Neuropathology and applied neurobiology.

[83]  J. Jia,et al.  Cerebrospinal fluid tau, Aβ1–42 and inflammatory cytokines in patients with Alzheimer's disease and vascular dementia , 2005, Neuroscience Letters.

[84]  J. Toldi,et al.  Role of kynurenines in the central and peripheral nervous systems. , 2005, Current neurovascular research.

[85]  M. Schultzberg,et al.  Soluble interleukin-1 receptor type II, IL-18 and caspase-1 in mild cognitive impairment and severe Alzheimer's disease , 2005, Neurochemistry International.

[86]  D. Fuchs,et al.  Monocyte-mediated T-cell suppression and augmented monocyte tryptophan catabolism after human hematopoietic stem-cell transplantation. , 2005, Blood.

[87]  Ariel Miller,et al.  Matrix Metalloproteinase-9, Its Tissue Inhibitor(TIMP)-1 and CRP in Alzheimer’s Disease , 2005, European Neurology.

[88]  M. Mimura,et al.  High Prevalence of Chlamydia Pneumoniae Antibodies and Increased High‐Sensitive C‐Reactive Protein in Patients with Vascular Dementia , 2005, Journal of the American Geriatrics Society.

[89]  C. Holmes,et al.  Association between Dementia and Infectious Disease: Evidence from a Case-Control Study , 2005, Alzheimer disease and associated disorders.

[90]  A. Batra,et al.  Diminished Production of Proinflammatory Cytokines in Patients with Alzheimer’s Disease , 2005, Dementia and Geriatric Cognitive Disorders.

[91]  F. Paoletti,et al.  Increased plasma levels of soluble CD40, together with the decrease of TGFβ1, as possible differential markers of Alzheimer disease , 2004, Experimental Gerontology.

[92]  K. Blennow,et al.  Increased cerebrospinal fluid levels of transforming growth factor-β1 in Alzheimer’s disease , 2004, Neuroscience Letters.

[93]  K. Nakashima,et al.  Elevated interleukin‐6 levels in cerebrospinal fluid of vascular dementia patients , 2004, Acta neurologica Scandinavica.

[94]  J. Raftery,et al.  Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial , 2004, The Lancet.

[95]  C. Paladini,et al.  Alzheimer Patients Treated With an AchE Inhibitor Show Higher IL-4 and Lower IL-1β Levels and Expression in Peripheral Blood Mononuclear Cells , 2004, Journal of clinical psychopharmacology.

[96]  A. Hofman,et al.  Inflammatory proteins in plasma and the risk of dementia: the rotterdam study. , 2004, Archives of neurology.

[97]  D. Gambi,et al.  Treatment with an acetylcholinesterase inhibitor in Alzheimer patients modulates the expression and production of the pro-inflammatory and anti-inflammatory cytokines , 2004, Journal of Neuroimmunology.

[98]  H. Steinbusch,et al.  Combination of serum markers related to several mechanisms in Alzheimer’s disease , 2003, Neurobiology of Aging.

[99]  Claudio Franceschi,et al.  Interleukin-6 gene alleles affect the risk of Alzheimer’s disease and levels of the cytokine in blood and brain , 2003, Neurobiology of Aging.

[100]  I. Appollonio,et al.  Peripheral cytokine release in Alzheimer patients: correlation with disease severity , 2003, Neurobiology of Aging.

[101]  K. Jellinger,et al.  The impact of cerebrovascular lesions in Alzheimer disease , 2003, Journal of Neurology.

[102]  T. del Ser,et al.  Cerebrospinal fluid markers in dementia with lewy bodies compared with Alzheimer disease. , 2003, Archives of neurology.

[103]  A. Słowik,et al.  Dexamethasone Inhibits TNF-α Synthesis More Effectively in Alzheimer’s Disease Patients than in Healthy Individuals , 2003, Dementia and Geriatric Cognitive Disorders.

[104]  A. Bossowski,et al.  Cytokines in patients with ischaemic heart disease or myocardial infarction. , 2003, Kardiologia polska.

[105]  W. Banks,et al.  Entry of Blood-Borne Cytokines into the Central Nervous System: Effects on Cognitive Processes , 2003, Neuroimmunomodulation.

[106]  K. Blennow,et al.  Inflammatory Markers in Matched Plasma and Cerebrospinal Fluid from Patients with Alzheimer’s Disease , 2003, Dementia and Geriatric Cognitive Disorders.

[107]  A. Evans,et al.  C-Reactive Protein, Interleukin-6, and Fibrinogen as Predictors of Coronary Heart Disease: The PRIME Study , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[108]  V. Perry,et al.  Systemic infection, interleukin 1β, and cognitive decline in Alzheimer’s disease , 2003, Journal of neurology, neurosurgery, and psychiatry.

[109]  S. Maier.  Bi-directional immune–brain communication: Implications for understanding stress, pain, and cognition , 2003, Brain, Behavior, and Immunity.

[110]  P. Scheltens,et al.  Chemokines in serum and cerebrospinal fluid of Alzheimer's disease patients , 2003, Annals of neurology.

[111]  Colm Cunningham,et al.  The impact of systemic infection on the progression of neurodegenerative disease , 2003, Nature Reviews Neuroscience.

[112]  H. Möller,et al.  Polymorphisms of the gene encoding the inflammatory cytokine interleukin-6 determine the magnitude of the increase in soluble interleukin-6 receptor levels in Alzheimer's disease , 2003, European Archives of Psychiatry and Clinical Neuroscience.

[113]  Kevin J. Tracey,et al.  The inflammatory reflex , 2002, Nature.

[114]  U. Hanisch,et al.  Microglia as a source and target of cytokines , 2002, Glia.

[115]  M. Tettamanti,et al.  Peripheral Inflammatory Response in Alzheimer's Disease and Multiinfarct Dementia , 2002, Neurobiology of Disease.

[116]  M. Mullan,et al.  Reduced Th1 and enhanced Th2 immunity after immunization with Alzheimer's β-amyloid1–42 , 2002, Journal of Neuroimmunology.

[117]  R. Schmidt,et al.  Early inflammation and dementia: A 25‐year follow‐up of the Honolulu‐Asia aging study , 2002, Annals of neurology.

[118]  R. Mrak,et al.  Interleukin‐1 in the genesis and progression of and risk for development of neuronal degeneration in Alzheimer’s disease , 2002, Journal of leukocyte biology.

[119]  S. Thompson,et al.  Quantifying heterogeneity in a meta‐analysis , 2002, Statistics in medicine.

[120]  R. Comolli,et al.  Decrease of TGF-β1 plasma levels and increase of nitric oxide synthase activity in leukocytes as potential biomarkers of Alzheimer's disease , 2002, Experimental Gerontology.

[121]  H. Baba,et al.  Effect of IL-6 polymorphism on risk of Alzheimer disease: genotype-phenotype association study in Japanese cases. , 2002, American journal of medical genetics.

[122]  H. Baba,et al.  The effect of IL4 +33C/T polymorphism on risk of Japanese sporadic Alzheimer's disease , 2002, Neuroscience Letters.

[123]  Anders Wallin,et al.  Increased intrathecal levels of the angiogenic factors VEGF and TGF-β in Alzheimer’s disease and vascular dementia , 2002, Neurobiology of Aging.

[124]  P. Cras,et al.  The role of cytokines, astrocytes, microglia and apoptosis in Creutzfeldt-Jakob disease , 2002, Neurobiology of Aging.

[125]  E. Porreca,et al.  Proinflammatory cytokines in sera of elderly patients with dementia: levels in vascular injury are higher than those of mild–moderate Alzheimer's disease patients , 2002, Experimental Gerontology.

[126]  Gerhard Ransmayr,et al.  Ibuprofen Decreases Cytokine-Induced Amyloid Beta Production in Neuronal Cells , 2001, Neurobiology of Disease.

[127]  J. Lindsay,et al.  Past exposure to vaccines and subsequent risk of Alzheimer's disease. , 2001, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[128]  U. Ikeda,et al.  Interleukin‐6 and acute coronary syndrome , 2001, Clinical cardiology.

[129]  M. Tettamanti,et al.  Inflammatory markers in Alzheimer's disease and multi-infarct dementia , 2001, Mechanisms of Ageing and Development.

[130]  K. Blennow,et al.  Local and systemic GM‐CSF increase in Alzheimer's disease and vascular dementia , 2001, Acta neurologica Scandinavica.

[131]  K. Jellinger,et al.  Intra vitam lumbar and post mortem ventricular cerebrospinal fluid immunoreactive interleukin‐6 in Alzheimer's disease patients , 2001, Acta neurologica Scandinavica.

[132]  B. Alescio-Lautier,et al.  Lithostathine and pancreatitis-associated protein are involved in the very early stages of Alzheimer’s disease , 2001, Neurobiology of Aging.

[133]  G. Annoni,et al.  Gene polymorphism affecting α1‐antichymotrypsin and interleukin‐1 plasma levels increases Alzheimer's disease risk , 2000, Annals of neurology.

[134]  W. Oertel,et al.  Association of an interleukin 1α polymorphism with Alzheimer’s disease , 2000, Neurology.

[135]  A. Suzumura,et al.  Increased Soluble Tumor Necrosis Factor Receptor Levels in the Serum of Elderly People , 2000, Gerontology.

[136]  K. Blennow,et al.  TNF gene polymorphism and its relation to intracerebral production of TNFα and TNFβ in AD , 2000, Neurology.

[137]  Á. Hernanz,et al.  Increased cerebrospinal fluid Fas (Apo-1) levels in Alzheimer’s disease Relationship with IL-6 concentrations , 2000, Brain Research.

[138]  C. Plata-salamán,et al.  Inflammation and Alzheimer’s disease , 2000, Neurobiology of Aging.

[139]  G. Rauch,et al.  Cardiovascular and Other Risk Factors for Alzheimer's Disease and Vascular Dementia , 2000, Annals of the New York Academy of Sciences.

[140]  R. Havlik,et al.  Midlife blood pressure and dementia: the Honolulu–Asia aging study☆ , 2000, Neurobiology of Aging.

[141]  G. Annoni,et al.  Increased plasma levels of interleukin-1, interleukin-6 and α-1-antichymotrypsin in patients with Alzheimer's disease: peripheral inflammation or signals from the brain? , 2000, Journal of Neuroimmunology.

[142]  E. Rogaev,et al.  Association between angiotensin-converting enzyme and Alzheimer disease. , 2000, Archives of neurology.

[143]  S. Humphries,et al.  Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? , 2000, Atherosclerosis.

[144]  S. Rivest,et al.  How the Blood Talks to the Brain Parenchyma and the Paraventricular Nucleus of the Hypothalamus During Systemic Inflammatory and Infectious Stimuli (44459) , 2000, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[145]  L. Fernández-Novoa,et al.  Double-blind placebo-controlled study with citicoline in APOE genotyped Alzheimer's disease patients. Effects on cognitive performance, brain bioelectrical activity and cerebral perfusion. , 1999, Methods and findings in experimental and clinical pharmacology.

[146]  D. Munn,et al.  Tryptophan catabolism and T-cell tolerance: immunosuppression by starvation? , 1999, Immunology today.

[147]  E. Bosmans,et al.  Inflammatory markers in younger vs elderly normal volunteers and in patients with Alzheimer's disease. , 1999, Journal of psychiatric research.

[148]  K. Blennow,et al.  Intracerebral Production of Tumor Necrosis Factor-α, a Local Neuroprotective Agent, in Alzheimer Disease and Vascular Dementia , 1999, Journal of Clinical Immunology.

[149]  S. Rivest,et al.  Effects of Systemic Immunogenic Insults and Circulating Proinflammatory Cytokines on the Transcription of the Inhibitory Factor κBα Within Specific Cellular Populations of the Rat Brain , 1999, Journal of neurochemistry.

[150]  R. Cacabelos,et al.  Characterization of cytokine production, screening of lymphocyte subset patterns and in vitro apoptosis in healthy and Alzheimer's Disease (AD) individuals , 1999, Journal of Neuroimmunology.

[151]  M. McCarty.  Interleukin-6 as a central mediator of cardiovascular risk associated with chronic inflammation, smoking, diabetes, and visceral obesity: down-regulation with essential fatty acids, ethanol and pentoxifylline. , 1999, Medical hypotheses.

[152]  H. Basun,et al.  Soluble interleukin-1 receptor type II levels are elevated in cerebrospinal fluid in Alzheimer's disease patients , 1999, Brain Research.

[153]  M. Herkenham,et al.  Time course and localization patterns of interleukin-1β messenger rna expression in brain and pituitary after peripheral administration of lipopolysaccharide , 1998, Neuroscience.

[154]  D G Altman,et al.  Confidence intervals for the number needed to treat , 1998, BMJ.

[155]  A. Smith,et al.  Longitudinal study of inflammatory factors in serum, cerebrospinal fluid, and brain tissue in Alzheimer disease: interleukin-1beta, interleukin-6, interleukin-1 receptor antagonist, tumor necrosis factor-alpha, the soluble tumor necrosis factor receptors I and II, and alpha1-antichymotrypsin. , 1998, Alzheimer disease and associated disorders.

[156]  E. Bosmans,et al.  Serotonin-immune interactions in elderly volunteers and in patients with Alzheimer’s disease (DAT): Lower plasma tryptophan availability to the brain in the elderly and increased serum interleukin-6 in DAT , 1998, Aging.

[157]  H. Link,et al.  IFN‐γ production of adult rat astrocytes triggered by TNF‐α , 1998 .

[158]  C. Brayne,et al.  Vascular Risks and Incident Dementia: Results from a Cohort Study of the Very Old , 1998, Dementia and Geriatric Cognitive Disorders.

[159]  N. Christophidis,et al.  Serum interleukin-6 and interleukin-6 soluble receptor in Alzheimer's disease , 1998, Neuroscience Letters.

[160]  M. Su,et al.  Interleukin-18 (IFNgamma-inducing factor) induces IL-8 and IL-1beta via TNFalpha production from non-CD14+ human blood mononuclear cells. , 1998, The Journal of clinical investigation.

[161]  C. Hock,et al.  Interleukin-6 (IL-6) and soluble forms of IL-6 receptors are not altered in cerebrospinal fluid of Alzheimer's disease patients , 1997, Neuroscience Letters.

[162]  V. Singh,et al.  Circulating cytokines in Alzheimer's disease. , 1997, Journal of psychiatric research.

[163]  F. Licastro,et al.  Monomeric and polymeric forms of alpha-1 antichymotrypsin in sera from patients with probable late onset Alzheimer's disease. , 1997, Dementia and geriatric cognitive disorders.

[164]  G. Smith,et al.  Bias in meta-analysis detected by a simple, graphical test , 1997, BMJ.

[165]  L. Fernández-Novoa,et al.  Cerebrovascular Changes Associated with Interleukin-1β (IL-1β) and Histamine (HA) Levels in Alzheimer's Disease , 1997 .

[166]  H. Möller,et al.  Interleukin-6 is not altered in cerebrospinal fluid of first-degree relatives and patients with Alzheimer's disease 1 Paper will be presented in part (Abstract) at the Meeting of the Society for Neuroscience, New Orleans, LA, USA in October 1997. 1 , 1997, Neuroscience Letters.

[167]  L. Fernández-Novoa,et al.  Blood levels of histamine, IL-1β, and TNF-α in patients with mild to moderate alzheimer disease , 1996 .

[168]  K. Davis,et al.  A pilot study of prednisone in Alzheimer's disease. , 1996, Dementia.

[169]  D. Coakley,et al.  Acute phase reactants in Alzheimer's disease , 1996, Biological Psychiatry.

[170]  Peter Riederer,et al.  Interleukin-1β and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients , 1995, Neuroscience Letters.

[171]  D. Sparks,et al.  Increased incidence of neurofibrillary tangles (NFT) in non-demented individuals with hypertension , 1995, Journal of the Neurological Sciences.

[172]  W. Banks,et al.  Passage of cytokines across the blood-brain barrier. , 1995, Neuroimmunomodulation.

[173]  R. Mrak,et al.  Interleukin‐1 Expression in Different Plaque Types in Alzheimer's Disease: Significance in Plaque Evalution , 1995, Journal of neuropathology and experimental neurology.

[174]  T. Hasegawa,et al.  Decreased interleukin-6 level in the cerebrospinal fluid of patients with Alzheimer-type dementia , 1995, Neuroscience Letters.

[175]  C. Begg,et al.  Operating characteristics of a rank correlation test for publication bias. , 1994, Biometrics.

[176]  W. Banks,et al.  Penetration of interleukin-6 across the murine blood-brain barrier , 1994, Neuroscience Letters.

[177]  H. Wiśniewski,et al.  α1-Antichymotrypsin and IL-1β are not increased in CSF or serum in Alzheimer's disease , 1994, Neurobiology of Aging.

[178]  W. Tourtellotte,et al.  Transforming growth factor beta in Alzheimer's disease , 1994, Clinical and diagnostic laboratory immunology.

[179]  R. Coffman,et al.  Interleukin‐4 and interleukin‐10 synergize to inhibit cell‐mediated immunity in vivo , 1993, European journal of immunology.

[180]  W. Banks,et al.  Murine tumor necrosis factor alpha is transported from blood to brain in the mouse , 1993, Journal of Neuroimmunology.

[181]  L. Fernández-Novoa,et al.  Effect of CDP‐Choline on Cognition and Immune Function in Alzheimer's Disease and Multi‐Infarct Dementia a , 1993 .

[182]  R. Coffman,et al.  Interleukin‐4 and interleukin‐10 synergize to inhibit cell‐mediated immunity in vivo , 1993, European journal of immunology.

[183]  M S Favero,et al.  Cytokine kinetics in an in vitro whole blood model following an endotoxin challenge. , 1993, Lymphokine and cytokine research.

[184]  Y. Vodovotz,et al.  Contrasting mechanisms for suppression of macrophage cytokine release by transforming growth factor-beta and interleukin-10. , 1992, The Journal of biological chemistry.

[185]  L. Fernández-Novoa,et al.  Effect of CDP-choline on cognition and immune function in Alzheimer's disease and multi-infarct dementia , 1992, European Neuropsychopharmacology.

[186]  E. Major,et al.  Human microglia convert l-tryptophan into the neurotoxin quinolinic acid. , 1992, The Biochemical journal.

[187]  H. Spits,et al.  Differential effects of IL-4 and IL-10 on IL-2-induced IFN-gamma synthesis and lymphokine-activated killer activity. , 1992, International immunology.

[188]  R. Nixon,et al.  Lysosomal hydrolases of different classes are abnormally distributed in brains of patients with Alzheimer disease. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[189]  M. Barquero,et al.  Cerebrospinal fluid interleukin-1 beta (IL-1 beta) in Alzheimer's disease and neurological disorders. , 1991, Methods and findings in experimental and clinical pharmacology.

[190]  L. Buée,et al.  Elevated circulating tumor necrosis factor levels in Alzheimer's disease , 1991, Neuroscience Letters.

[191]  R. Schwarcz,et al.  Blood–Brain Barrier Transport of Kynurenines: Implications for Brain Synthesis and Metabolism , 1991, Journal of neurochemistry.

[192]  T. Mosmann,et al.  IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells. , 1991, Journal of immunology.

[193]  A. Hofman,et al.  Serum levels of interleukin-6 are not elevated in patients with Alzheimer's disease , 1990, Neuroscience Letters.

[194]  W. Griffin,et al.  Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[195]  K. Jellinger,et al.  Accumulation of abnormally phosphorylated τ precedes the formation of neurofibrillary tangles in Alzheimer's disease , 1989, Brain Research.

[196]  M. Eastwood,et al.  Stress and coronary heart disease. , 1971, Journal of psychosomatic research.

[197]  K. Jellinger.  Intrathecal levels of IL-6 in Alzheimer’s disease , 2009, Journal of Neurology.

[198]  Niklas K. U. Koehler,et al.  Decline of Immune Responsiveness: A Pathogenetic Factor in Alzheimer's Disease? , 2009 .

[199]  J. Talbott,et al.  Cardiorespiratory fitness and brain atrophy in early Alzheimer disease , 2009 .

[200]  K. Jellinger,et al.  Clinical significance of neurobiochemical profiles in the lumbar cerebrospinal fluid of Alzheimer’s disease patients , 2009, Journal of Neural Transmission.

[201]  M. Schwartz,et al.  Koronyo-Hamaoui, M. et al. Attenuation of AD-like neuropathology by harnessing peripheral immune cells: local elevation of IL-10 and MMP-9. J. Neurochem. 111, 1409-1424 , 2009 .

[202]  A. Alajbegović,et al.  Elevated serum C-reactive protein concentration in Bosnian patients with probable Alzheimer's disease. , 2007, Journal of Alzheimer's disease : JAD.

[203]  V. Haroutunian,et al.  Coronary artery disease is associated with Alzheimer disease neuropathology in APOE4 carriers. Authors' reply , 2007 .

[204]  K. Welsh-Bohmer,et al.  Coronary artery disease is associated with Alzheimer disease neuropathology in APOE4 carriers. , 2007, Neurology.

[205]  B. Bergamasco,et al.  Increased intrathecal TGF-beta1, but not IL-12, IFN-gamma and IL-10 levels in Alzheimer's disease patients. , 2006, Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology.

[206]  Andrew Cordle,et al.  Neurobiology of Disease 3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Inhibitors Attenuate-Amyloid-Induced Microglial Inflammatory Responses , 2005 .

[207]  F. Sherriff,et al.  Memantine for dementia. , 2005, The Cochrane database of systematic reviews.

[208]  K. Blennow,et al.  Increased cerebrospinal fluid levels of transforming growth factor-beta1 in Alzheimer's disease. , 2004, Neuroscience letters.

[209]  R. Comolli,et al.  Decrease of TGF-beta1 plasma levels and increase of nitric oxide synthase activity in leukocytes as potential biomarkers of Alzheimer's disease. , 2002, Experimental gerontology.

[210]  M. Mullan,et al.  Reduced Th1 and enhanced Th2 immunity after immunization with Alzheimer's beta-amyloid(1-42). , 2002, Journal of neuroimmunology.

[211]  D. Cucinotta,et al.  Alpha-1-antichymotrypsin and oxidative stress in the peripheral blood from patients with probable Alzheimer disease: a short-term longitudinal study. , 2001, Alzheimer disease and associated disorders.

[212]  D. Fuchs,et al.  Tryptophan degradation and immune activation in Alzheimer's disease , 2000, Journal of Neural Transmission.

[213]  S. Paul,et al.  Association of an interleukin 1 alpha polymorphism with Alzheimer's disease. , 2000, Neurology.

[214]  H. Link,et al.  IFN-gamma production of adult rat astrocytes triggered by TNF-alpha. , 1998, Neuroreport.

[215]  L. Fernández-Novoa,et al.  Cerebrovascular changes associated with interleukin-1 beta (IL-1 beta) and histamine (HA) levels in Alzheimer's disease. , 1997, Annals of the New York Academy of Sciences.

[216]  P Riederer,et al.  Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients. , 1995, Neuroscience letters.

[217]  L. Fernández-Novoa,et al.  Serum tumor necrosis factor (TNF) in Alzheimer's disease and multi-infarct dementia. , 1994, Methods and findings in experimental and clinical pharmacology.

[218]  S. Markey,et al.  Human macrophages convert L-tryptophan into the neurotoxin quinolinic acid. , 1992, The Biochemical journal.